{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T22:35:20Z","timestamp":1783809320482,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"crossref","award":["2020J011117"],"award-info":[{"award-number":["2020J011117"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Joint Funds for the innovation of science and Technology","award":["2019Y9040"],"award-info":[{"award-number":["2019Y9040"]}]},{"DOI":"10.13039\/501100017686","name":"Fujian Provincial Health Technology Project","doi-asserted-by":"publisher","award":["2022CXA027"],"award-info":[{"award-number":["2022CXA027"]}],"id":[{"id":"10.13039\/501100017686","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-023-01068-3","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T17:01:59Z","timestamp":1682614919000},"page":"3767-3780","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin\u2019s lymphoma"],"prefix":"10.1007","volume":"23","author":[{"given":"Lin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuling","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuliang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengqiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangliang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"1068_CR1","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","volume":"40","author":"H Zhang","year":"2021","unstructured":"Zhang H, Dai Z, Wu W, et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer Res. 2021;40:184. https:\/\/doi.org\/10.1186\/s13046-021-01987-7.","journal-title":"J Exp Clin Cancer Res"},{"key":"1068_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18:153\u201367. https:\/\/doi.org\/10.1038\/nri.2017.108.","journal-title":"Nat Rev Immunol"},{"key":"1068_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","volume":"131","author":"ZY Xu-Monette","year":"2018","unstructured":"Xu-Monette ZY, Zhou J, Young KH. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood. 2018;131:68\u201383. https:\/\/doi.org\/10.1182\/blood-2017-07-740993.","journal-title":"Blood"},{"key":"1068_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372:311\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1411087.","journal-title":"N Engl J Med"},{"key":"1068_CR5","doi-asserted-by":"publisher","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-10-2660","volume":"17","author":"DJ Andorsky","year":"2011","unstructured":"Andorsky DJ, Yamada RE, Said J, et al. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011;17:4232\u201344. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2660.","journal-title":"Clin Cancer Res"},{"key":"1068_CR6","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","volume":"19","author":"BJ Chen","year":"2013","unstructured":"Chen BJ, Chapuy B, Ouyang J, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013;19:3462\u201373. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0855.","journal-title":"Clin Cancer Res"},{"key":"1068_CR7","doi-asserted-by":"publisher","first-page":"382","DOI":"10.4049\/immunohorizons.1900053","volume":"4","author":"S Sawasdikosol","year":"2020","unstructured":"Sawasdikosol S, Zha R, Fisher TS, et al. HPK1 Influences Regulatory T Cell Functions. Immunohorizons. 2020;4:382\u201391. https:\/\/doi.org\/10.4049\/immunohorizons.1900053.","journal-title":"Immunohorizons"},{"key":"1068_CR8","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.55122","author":"S Sawasdikosol","year":"2020","unstructured":"Sawasdikosol S, Burakoff S. A perspective on HPK1 as a novel immuno-oncology drug target. Elife. 2020. https:\/\/doi.org\/10.7554\/eLife.55122.","journal-title":"Elife"},{"key":"1068_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/ni1416","volume":"8","author":"JW Shui","year":"2007","unstructured":"Shui JW, Boomer JS, Han J, et al. Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell-mediated immune responses. Nat Immunol. 2007;8:84\u201391. https:\/\/doi.org\/10.1038\/ni1416.","journal-title":"Nat Immunol"},{"key":"1068_CR10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.celrep.2018.09.012","volume":"25","author":"S Hernandez","year":"2018","unstructured":"Hernandez S, Qing J, Thibodeau RH, et al. The kinase activity of hematopoietic progenitor kinase 1 is essential for the regulation of T cell function. Cell Rep. 2018;25:80\u201394. https:\/\/doi.org\/10.1016\/j.celrep.2018.09.012.","journal-title":"Cell Rep"},{"key":"1068_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001402","author":"D You","year":"2021","unstructured":"You D, Hillerman S, Locke G, et al. Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2020-001402.","journal-title":"J Immunother Cancer"},{"key":"1068_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51:27\u201341. https:\/\/doi.org\/10.1016\/j.immuni.2019.06.025.","journal-title":"Immunity"},{"key":"1068_CR13","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.cell.2010.01.040","volume":"140","author":"K Schroder","year":"2010","unstructured":"Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140:821\u201332. https:\/\/doi.org\/10.1016\/j.cell.2010.01.040.","journal-title":"Cell"},{"key":"1068_CR14","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1172\/JCI133055","volume":"130","author":"B Theivanthiran","year":"2020","unstructured":"Theivanthiran B, Evans KS, DeVito NC, et al. A tumor-intrinsic PD-L1\/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy. J Clin Invest. 2020;130:2570\u201386. https:\/\/doi.org\/10.1172\/JCI133055.","journal-title":"J Clin Invest."},{"key":"1068_CR15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.canlet.2020.10.024","volume":"497","author":"F Lu","year":"2021","unstructured":"Lu F, Zhao Y, Pang Y, et al. NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma. Cancer Lett. 2021;497:178\u201389. https:\/\/doi.org\/10.1016\/j.canlet.2020.10.024.","journal-title":"Cancer Lett"},{"key":"1068_CR16","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s11899-020-00589-y","volume":"15","author":"W Xie","year":"2020","unstructured":"Xie W, Medeiros LJ, Li S, et al. PD-1\/PD-L1 pathway and its blockade in patients with classic hodgkin lymphoma and non-hodgkin large-cell lymphomas. Curr Hematol Malig Rep. 2020;15:372\u201381. https:\/\/doi.org\/10.1007\/s11899-020-00589-y.","journal-title":"Curr Hematol Malig Rep"},{"key":"1068_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155456","author":"A Kuzume","year":"2020","unstructured":"Kuzume A, Chi S, Yamauchi N, et al. Immune-Checkpoint Blockade Therapy in Lymphoma. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21155456.","journal-title":"Int J Mol Sci"},{"key":"1068_CR18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/ni.2224","volume":"13","author":"L Zitvogel","year":"2012","unstructured":"Zitvogel L, Kepp O, Galluzzi L, et al. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol. 2012;13:343\u201351. https:\/\/doi.org\/10.1038\/ni.2224.","journal-title":"Nat Immunol"},{"key":"1068_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41568-019-0123-y","volume":"19","author":"R Karki","year":"2019","unstructured":"Karki R, Kanneganti TD. Diverging inflammasome signals in tumorigenesis and potential targeting. Nat Rev Cancer. 2019;19:197\u2013214. https:\/\/doi.org\/10.1038\/s41568-019-0123-y.","journal-title":"Nat Rev Cancer"},{"key":"1068_CR20","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.08.001","volume":"38","author":"J Si","year":"2020","unstructured":"Si J, Shi X, Sun S, et al. Hematopoietic progenitor kinase1 (HPK1) mediates T cell dysfunction and is a druggable target for T cell-based immunotherapies. Cancer Cell. 2020;38:551\u201366. https:\/\/doi.org\/10.1016\/j.ccell.2020.08.001.","journal-title":"Cancer Cell."},{"key":"1068_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001895","author":"C Liu","year":"2021","unstructured":"Liu C, Liu R, Wang B, et al. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2020-001895.","journal-title":"J Immunother Cancer."},{"key":"1068_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","volume":"13","author":"DN Khalil","year":"2016","unstructured":"Khalil DN, Smith EL, Brentjens RJ, et al. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13:273\u201390. https:\/\/doi.org\/10.1038\/nrclinonc.2016.25.","journal-title":"Nat Rev Clin Oncol"},{"key":"1068_CR23","doi-asserted-by":"publisher","first-page":"0243145","DOI":"10.1371\/journal.pone.0243145","volume":"15","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang K, Georgiev P, et al. Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function. PLoS One. 2020;15:0243145. https:\/\/doi.org\/10.1371\/journal.pone.0243145.","journal-title":"PLoS One."},{"key":"1068_CR24","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1080\/13543776.2021.1924671","volume":"31","author":"ID Linney","year":"2021","unstructured":"Linney ID, Kaila N. Inhibitors of immuno-oncology target HPK1\u2013\u2013a patent review (2016 to 2020). Expert Opin Ther Pat. 2021;31:893\u2013910. https:\/\/doi.org\/10.1080\/13543776.2021.1924671.","journal-title":"Expert Opin Ther Pat"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01068-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-023-01068-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01068-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T20:16:01Z","timestamp":1698783361000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-023-01068-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":24,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["1068"],"URL":"https:\/\/doi.org\/10.1007\/s10238-023-01068-3","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]},"assertion":[{"value":"15 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}